Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.

Hideshima H, Yoshida Y, Ikeda H, Hide M, Iwasaki A, Anderson KC, Hideshima T.

Int J Oncol. 2014 Apr;44(4):1171-6. doi: 10.3892/ijo.2014.2273.

2.

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.

Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC.

Blood. 2009 Jul 30;114(5):1046-52. doi: 10.1182/blood-2009-01-199604.

3.

Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.

Juvekar A, Manna S, Ramaswami S, Chang TP, Vu HY, Ghosh CC, Celiker MY, Vancurova I.

Mol Cancer Res. 2011 Feb;9(2):183-94. doi: 10.1158/1541-7786.MCR-10-0368.

5.

Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.

Tamatani T, Takamaru N, Hara K, Kinouchi M, Kuribayashi N, Ohe G, Uchida D, Fujisawa K, Nagai H, Miyamoto Y.

Int J Oncol. 2013 Mar;42(3):935-44. doi: 10.3892/ijo.2013.1786.

PMID:
23340716
7.

Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.

Bu R, Hussain AR, Al-Obaisi KA, Ahmed M, Uddin S, Al-Kuraya KS.

Leuk Lymphoma. 2014 Feb;55(2):415-24. doi: 10.3109/10428194.2013.806799.

PMID:
23697845
9.

The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, Neeser J, Mikail A, Adams J, Sjak-Shie N, Vescio RA, Berenson JR.

Clin Cancer Res. 2003 Mar;9(3):1136-44.

10.

Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.

Li C, Chen S, Yue P, Deng X, Lonial S, Khuri FR, Sun SY.

J Biol Chem. 2010 May 21;285(21):16096-104. doi: 10.1074/jbc.M109.072694.

11.

The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.

Berenson JR, Ma HM, Vescio R.

Semin Oncol. 2001 Dec;28(6):626-33. Review.

PMID:
11740821
12.

Trichothecin induces cell death in NF-κB constitutively activated human cancer cells via inhibition of IKKβ phosphorylation.

Su J, Zhao P, Kong L, Li X, Yan J, Zeng Y, Li Y.

PLoS One. 2013 Aug 1;8(8):e71333. doi: 10.1371/journal.pone.0071333.

13.

Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells.

Singha B, Gatla HR, Manna S, Chang TP, Sanacora S, Poltoratsky V, Vancura A, Vancurova I.

J Biol Chem. 2014 Jan 31;289(5):2687-700. doi: 10.1074/jbc.M113.502641.

14.

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.

Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S.

Mol Cancer. 2008 May 19;7:40. doi: 10.1186/1476-4598-7-40.

15.

The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.

Wang H, Wang X, Li Y, Liao A, Fu B, Pan H, Liu Z, Yang W.

Pharmazie. 2012 Feb;67(2):187-92.

PMID:
22512091
16.

Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells.

Jia L, Gopinathan G, Sukumar JT, Gribben JG.

PLoS One. 2012;7(2):e32584. doi: 10.1371/journal.pone.0032584.

17.

Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.

Allen C, Saigal K, Nottingham L, Arun P, Chen Z, Van Waes C.

Clin Cancer Res. 2008 Jul 1;14(13):4175-85. doi: 10.1158/1078-0432.CCR-07-4470.

18.

NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.

Amschler K, Schön MP, Pletz N, Wallbrecht K, Erpenbeck L, Schön M.

J Invest Dermatol. 2010 Apr;130(4):1073-86. doi: 10.1038/jid.2009.365.

19.

Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.

Dai Y, Chen S, Wang L, Pei XY, Kramer LB, Dent P, Grant S.

Br J Haematol. 2011 Apr;153(2):222-35. doi: 10.1111/j.1365-2141.2011.08591.x.

20.

Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.

Denlinger CE, Rundall BK, Keller MD, Jones DR.

Ann Thorac Surg. 2004 Oct;78(4):1207-14; discussion 1207-14.

PMID:
15464472
Items per page

Supplemental Content

Support Center